|
|
||||||||
Published online before print May 30, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
,
,
,
,
Departments of *Pharmacology,
Gastroenterological Surgery, Transplant, and Surgical Oncology, and
Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan; and
Novartis Institutes for Biomedical Research, Basel, Switzerland
@ To whom correspondence should be addressed. E-mail: mbori{at}md.okayama-u.ac.jp.
| Abstract |
|---|
Statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase, are thought to reduce the risk of cancer through the inhibition of Ras farnesylation and serum lipid level. A pleiotropic proinflammatory cytokine, interleukin-18 (IL-18), is reported to exhibit significant antitumor activities through the activation of cytotoxic T lymphocytes and natural killer cells and the inhibition of angiogenesis. Previously, we found that pravastatin, fluvastatin, and simvastatin induced the production of IL-18 in human monocytes. The addition of mevalonate abolished the IL-18 production induced by pravastatin, fluvastatin, and simvastatin, indicating that the IL-18 production might be a result of the inhibition of HMG-CoA reductase. We present a new hypothesis that the production of IL-18 might play roles in the action of statins on cancer.
Key Words: statin cancer
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |